Shares of Autolus Therapeutics Ltd – (NASDAQ:AUTL) have been assigned a consensus rating of “Buy” from the five ratings firms that are covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $45.50.

A number of research firms recently issued reports on AUTL. HC Wainwright set a $18.00 price objective on Sutro Biopharma and gave the company a “buy” rating in a research report on Friday, May 17th. William Blair began coverage on American Software in a research report on Wednesday, April 3rd. They set an “outperform” rating and a $12.03 price objective for the company. Finally, Zacks Investment Research upgraded General Moly from a “sell” rating to a “hold” rating in a research report on Thursday, July 11th.

NASDAQ:AUTL traded down $0.47 during midday trading on Friday, reaching $15.24. 59,827 shares of the company traded hands, compared to its average volume of 124,203. Autolus Therapeutics has a twelve month low of $14.57 and a twelve month high of $53.24. The stock has a market capitalization of $630.69 million and a price-to-earnings ratio of -10.73. The company has a quick ratio of 10.66, a current ratio of 10.66 and a debt-to-equity ratio of 0.12. The firm has a fifty day moving average of $16.44.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.11). The company had revenue of $1.96 million during the quarter, compared to analyst estimates of $0.30 million. On average, sell-side analysts predict that Autolus Therapeutics will post -3.07 earnings per share for the current year.

Institutional investors have recently made changes to their positions in the business. BlackRock Inc. raised its stake in Autolus Therapeutics by 4,011.3% during the 4th quarter. BlackRock Inc. now owns 202,973 shares of the company’s stock valued at $6,666,000 after acquiring an additional 198,036 shares in the last quarter. CWM LLC bought a new stake in Autolus Therapeutics during the 1st quarter valued at $1,105,000. Marshall Wace LLP raised its stake in Autolus Therapeutics by 93.4% during the 1st quarter. Marshall Wace LLP now owns 232,931 shares of the company’s stock valued at $7,330,000 after acquiring an additional 112,489 shares in the last quarter. Barclays PLC bought a new stake in Autolus Therapeutics during the 4th quarter valued at $113,000. Finally, Geode Capital Management LLC bought a new stake in Autolus Therapeutics during the 4th quarter valued at $322,000. 43.37% of the stock is currently owned by hedge funds and other institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.

Recommended Story: What is the return on assets (ROA) ratio?

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.